Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it ...

Request To Download Free Sample of This Strategic Report @- Cardiovascular genetic testing enables clinicians and patients to identify inherited risks for a wide range of cardiac disorders, including ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else ...

OKLAHOMA CITY (KFOR) — Demolition began this week on the old Myriad Convention Center in downtown Oklahoma City. Earlier this week, the pedestrian skybridge was the first to come down, and now ...

Detailed price information for Arcus Biosciences Inc (RCUS-N) from The Globe and Mail including charting and trades.

By Josh Beckerman Shares of Myriad Genetics were higher after it announced early access to the FirstGene Multiple Prenatal Screen.

Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular ...

Methods: Multivariable logistic regression models were constructed to analyze trends in the prevalence of PVs based on age and FH in a consecutive cohort of patients referred for hereditary cancer ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Fintel reports that on May 8, 2025, Wells Fargo downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 281.44% Upside As of ...

Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular ...